Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver

Key facts

Sponsor

Emory University

Principal Investigator

John Horan, MD

Children's Healthcare of Atlanta

Intervention

Defibrotide(drug)

Eligibility

1-22 years · All sexes

Timeline

2005 – 2009

Study locations (1)

• Children's Healthcare of Atlanta, Atlanta, Georgia, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hepatic veno-occlusive disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT05987124
  Defibrotide Dose-escalation for SOS Post-HSCT
  New York Medical College
• RECRUITINGNCT06715046
  Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
  University of Turin, Italy
• RECRUITINGNCT05090345
  A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
  Duke University
• ACTIVE NOT RECRUITINGNANCT03865589
  Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
  Children's Mercy Hospital Kansas City

See all trials for Hepatic veno-occlusive disease →